New Marker of Amyotrophic Lateral Sclerosis (ALS) Outcome Discovered

In patients with Amyotrophic Lateral Sclerosis (ALS) a novel marker helps predict the clinical outcome through magnetoencephalography. This marker can be measured in the brain during its resting state and highlights the importance of brain flexibility for ALS patients. The study has been led by the Institut de Neurosciences des Systèmes in Marseille, in collaboration with Consiglio Nazionale delle Ricerche, Parthenope University of Naples and Institute of Diagnosis and Care Hermitage Capodimonte in Naples, and the Monash University in Melbourne. It was published online on Sept 30th, 2022, in Neurology, the medical journal of the American Academy of Neurology.

What is Amyotrophic Lateral Sclerosis (ALS)

ALS is a neurodegenerative disease of the brain and spinal cord that causes loss of muscle control. The ability of moving, speaking and, eventually, breathing is progressively impaired. There is no known cure but treatments to improve symptoms, including magnetic stimulation, are being tested. “The behaviour of the brain of an ALS patient is often hard to understand. The impairments can be caused by neuronal dysfunction of a small area of the brain that influences a much larger area, meaning you need whole brain scans to make predictions of the clinical outcome,” explains Pierpaolo Sorrentino from the INS, the last author of the study. “Patients can struggle with motor tasks during the scans. This new method, instead, can be applied to the brain at rest, making it easier for the patients and more consistent.”

Magnetoencephalography for Detecting Amyotropic Lateral Sclerosis

The researchers collected magnetoencephalography data on 42 ALS patients and 42 healthy controls at the University Parthenope in Naples, whose MEG facilities have recently become part of the EBRAINS network. The new study builds on previous work by the same group, which applied the methodology to Parkinson’s disease. “A healthy brain is a flexible one, capable of reconfiguring itself to respond to stimuli, triggering neuronal avalanches across different areas,” adds Sorrentino. “Think of it as a goalkeeper waiting for a penalty kick. If you are fast enough, constantly moving rather than standing in the same place is a better strategy for being ready for most possible trajectories.”

“The neuronal avalanches spread in patterns which we can monitor with whole-brain scans,” explains Arianna Polverino of the Institute of Diagnosis and Care Hermitage Capodimonte, lead author of the study. “We call the collection of all unique patterns the ‘functional repertoire’, a measurement of the flexibility of the brain.” The researchers focused on quantifying the functional repertoire of ALS brains, even when the patient is unprompted and the brain is in a resting state. “We found that a restriction of the functional repertoire corresponded to a more severe functional impairment. The more flexible the brain, the better the clinical outcome: the functional repertoire can be used as a reliable predictor of how the clinical outlook of a patient will likely evolve.”

“It is often difficult to tell how a particular therapy is working - now we might have a strong marker to predict its outcome,” says Sorrentino. The next step, according to the scientists, is to use this non-invasive readout in a longitudinal study that tracks the evolution of the disease in a patient-specific way and adjust treatment accordingly.

Source-Eurekalert